Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Search
Drug Profile

Panitumumab - Amgen

Alternative Names: ABX-EGF; Anti-EGFR monoclonal antibody - Abgenix; Clone-E7.6.3; E7.6.3; Panitumab; rHuMAb-EGFr; Vectibix

Latest Information Update: 13 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Grupo Espanol Multidisciplinario del Cancer Digestivo; Hellenic Cooperative Oncology Group; Netherlands Cancer Institute; Novartis; Takeda; University of Texas M. D. Anderson Cancer Center; Wissenschaftlicher Service Pharma
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer
  • Phase II Anal cancer; Bladder cancer; Breast cancer; Gastric cancer; Neuroendocrine tumours; Oesophageal cancer; Pancreatic cancer; Rectal cancer; Triple negative breast cancer
  • Phase I/II Solid tumours
  • Discontinued Head and neck cancer; Malignant melanoma; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 31 May 2024 Updated efficacy and adverse events data from a phase III trial in Colorectal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 31 May 2024 Efficacy and adverse events data from the phase II MONARCC trial in Colorectal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 02 May 2024 Phase-III clinical trials in Colorectal cancer (Metastatic disease, Combination therapy, First-line therapy) in South Korea (IV) (NCT06252649)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

New Timelines Chart

We recently added a timeline chart on all drug profiles. You can choose the indication from the drop down menu near the top. The chart will show the time the drug spent in different phases as it progressed through development for that indication. The end result is a Gantt style chart illustrating how long the drug took in each phase. This new chart takes advantage of our longitudinal pipeline data which we have stored every month since 2004. Please use the thumbs up/down buttons to let us know your opinion about this new feature.